Get the Stockscreener App
7.06
0.71%
0.05
After Hours:
7.20
0.14
+1.98%
Alpha Tau Medical Ltd stock is traded at $7.06, with a volume of 210.89K.
It is up +0.71% in the last 24 hours and down -16.15% over the past month.
Alpha Tau Medical Ltd is a clinical-stage oncology therapeutics company focused on harnessing the innate relative biological effectiveness and short range of alpha particles for use as a localized radiation therapy for solid tumors. Its proprietary Alpha DaRT technology is designed to utilize the specific therapeutic properties of alpha particles while aiming to overcome, and even harness for potential benefit, the traditional shortcomings of alpha radiation's limited range. The company has active clinical programs targeting a range of different tumor types, such as head and neck cancer, pancreatic cancer, brain cancer, liver metastases, lung cancer, and prostate cancer. Geographically, it operates in Israel, United States, and Japan with the majority of the revenue generated from Israel.
See More
Previous Close:
$7.01
Open:
$7.21
24h Volume:
210.89K
Relative Volume:
0.64
Market Cap:
$621.35M
Revenue:
-
Net Income/Loss:
$-42.63M
P/E Ratio:
-13.37
EPS:
-0.5281
Net Cash Flow:
$-39.43M
1W Performance:
-3.42%
1M Performance:
-16.15%
6M Performance:
+69.71%
1Y Performance:
+165.41%
1-Day Range:
$6.80
$7.30
1-Week Range:
$6.80
$7.52
52-Week Range:
$2.30
$8.60
Alpha Tau Medical Ltd Stock (DRTS) Company Profile
Compare DRTS vs VRTX, REGN, ALNY, ARGX, INSM
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
DRTS
Alpha Tau Medical Ltd
|
7.06 | 616.95M | 0 | -42.63M | -39.43M | -0.5281 |
VRTX
Vertex Pharmaceuticals Inc
|
454.97 | 113.96B | 12.07B | 3.95B | 3.19B | 15.33 |
REGN
Regeneron Pharmaceuticals Inc
|
749.47 | 78.41B | 14.34B | 4.50B | 3.77B | 41.56 |
ALNY
Alnylam Pharmaceuticals Inc
|
328.70 | 40.85B | 3.71B | 313.75M | 465.38M | 2.2571 |
ARGX
Argen X Se Adr
|
697.05 | 42.05B | 4.16B | 1.29B | 734.26M | 19.58 |
INSM
Insmed Inc
|
148.31 | 29.99B | 606.42M | -1.28B | -997.58M | -6.403 |
Alpha Tau Medical Ltd Stock (DRTS) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Mar-04-26 | Downgrade | Piper Sandler | Overweight → Neutral |
| Dec-15-23 | Initiated | Citigroup | Buy |
| Apr-24-23 | Initiated | H.C. Wainwright | Buy |
| Apr-14-22 | Initiated | Cantor Fitzgerald | Overweight |
| Apr-08-22 | Initiated | Piper Sandler | Overweight |
| Apr-04-22 | Initiated | Citigroup | Buy |
View All
Alpha Tau Medical Ltd Stock (DRTS) Latest News
Movement Recap: Should I invest in Alpha Tau Medical Ltd before earningsRisk Management & Target Return Focused Stock Picks - baoquankhu1.vn
Alpha Tau Medical Ltd. (DRTS) Competitors - Meyka
Alpha Tau Medical: 2026 Is The Breakthrough Year - Seeking Alpha
What is the Moat Score of Alpha Tau Medical Ltd2026 Closing Moves & Consistent Return Investment Signals - baoquankhu1.vn
Aug Action: Is Alpha Tau Medical Ltd Equity Warrant benefiting from interest rate changes2026 Winners & Losers & Safe Capital Growth Tips - baoquankhu1.vn
Is Alpha Tau Medical Ltd forming a bullish divergence2026 Year in Review & Real-Time Buy Signal Notifications - baoquankhu1.vn
Alpha Tau Medical (NASDAQ:DRTS) Shares Gap UpHere's Why - MarketBeat
Alpha Tau Medical Conference: Japan Approval, Rolling FDA PMA, and Big 2026 Data Readouts Teased - MarketBeat
Resistance Check: Is Alpha Tau Medical Ltd Equity Warrant benefiting from interest rate changesRate Hike & Daily Volume Surge Signals - baoquankhu1.vn
Alpha Tau Medical (DRTS) director details shares, options and RSUs - Stock Titan
Alpha Tau (DRTS) director discloses initial shares, RSUs and options - Stock Titan
Alpha Tau Medical (NASDAQ: DRTS) CEO details equity holdings - Stock Titan
Alpha Tau Medical (DRTS) director Alan Adler details share and option holdings - Stock Titan
Alpha Tau Medical (DRTS) director discloses shares, RSUs and options - Stock Titan
Alpha Tau Medical (DRTS) director details shares, options and warrants - Stock Titan
Alpha Tau Medical (NASDAQ: DRTS) director discloses initial shares, RSUs and option grants - Stock Titan
Alpha Tau Medical (NASDAQ: DRTS) director details initial equity holdings - Stock Titan
Alpha Tau Medical (DRTS) CFO Raphi Levy reports detailed insider holdings - Stock Titan
Pullback Watch: Can Alpha Tau Medical Ltd Equity Warrant reach all time highs this year2026 Top Gainers & Safe Swing Trade Setups - baoquankhu1.vn
Aug EndMonth: Will Alpha Tau Medical Ltd Equity Warrant benefit from rising consumer demandPortfolio Gains Report & Short-Term Trading Opportunity Alerts - baoquankhu1.vn
Is Alpha Tau Medical Ltd stock showing strong momentum2026 Spike Watch & High Accuracy Swing Entry Alerts - baoquankhu1.vn
Market Recap: Is Alpha Tau Medical Ltd Equity Warrant stock overvalued or fairly priced2026 Trading Volume Trends & Weekly Stock Breakout Alerts - baoquankhu1.vn
CFO Raphi Levy to pitch Alpha Tau to investors at Sidoti event this week - Stock Titan
Citigroup maintains Alpha Tau Medical (DRTS) buy recommendation - MSN
Alpha Tau Medical to Present at Sidoti March Virtual Small Cap Conference - geneonline.com
Piper Sandler cuts Alpha Tau Medical stock rating on valuation By Investing.com - Investing.com Nigeria
Alpha Tau Medical’s innovative prostate cancer therapy: study completion update - MSN
Fund Flows: What is the PEG ratio of Alpha Tau Medical Ltd2026 Institutional Moves & Low Risk Entry Point Tips - baoquankhu1.vn
Citigroup Forecasts Strong Price Appreciation for Alpha Tau Medical (NASDAQ:DRTS) Stock - Defense World
HC Wainwright Has Negative Estimate for DRTS Q1 Earnings - Defense World
Short Squeeze: Will Alpha Tau Medical Ltd benefit from rate cuts2026 Fundamental Recap & Low Drawdown Momentum Ideas - baoquankhu1.vn
HC Wainwright Issues Pessimistic Estimate for DRTS Earnings - MarketBeat
Citigroup Increases Alpha Tau Medical (NASDAQ:DRTS) Price Target to $9.00 - MarketBeat
Alpha Tau Medical (NASDAQ:DRTS) Given Buy Rating at HC Wainwright - Defense World
HC Wainwright Reaffirms "Buy" Rating for Alpha Tau Medical (NASDAQ:DRTS) - MarketBeat
Alpha Tau Medical: U.S. Trial Expansion, Japan Approval, and Manufacturing Scale-Up Support Buy Rating Despite Near-Term Losses - TipRanks
Alpha Tau Medical (NASDAQ:DRTS) Issues Earnings Results, Misses Estimates By $0.01 EPS - MarketBeat
DRTS: Alpha DaRT shows promising efficacy in solid tumors, with pivotal trials and global expansion ongoing - TradingView
Alpha Tau Posts Wider 2025 Loss as Japanese Approval and U.S. Trial Progress Mark Pivotal Year - TipRanks
Alpha Tau Medical (NASDAQ: DRTS) outlines 2025 loss and Oramed financing - Stock Titan
Alpha Tau (NASDAQ: DRTS) widens 2025 loss but gains Japan approval, $76.9M cash - Stock Titan
Alpha Tau Medical Ltd. Reports Earnings Results for the Full Year Ended December 31, 2025 - marketscreener.com
Alpha Tau cancer therapy wins Japan nod, targets tough tumors - Stock Titan
DRTS: 2025 net loss widened to $42.6M; cash reserves at $76.9M; pivotal trials and commercialization ongoing - TradingView
Trade Report: Is Alpha Tau Medical Ltd Equity Warrant stock a good pick for beginners2026 Volatility Report & AI Enhanced Trading Alerts - baoquankhu1.vn
Is Alpha Tau Medical Ltd. Equity Warrant benefiting from interest rate changesPortfolio Value Summary & Growth-Oriented Investment Plans - mfd.ru
Alpha Tau Medical Ltd. (NASDAQ:DRTS) Receives $7.00 Average PT from Analysts - Defense World
Piper Sandler Reaffirms Neutral Rating for Alpha Tau Medical (NASDAQ:DRTS) - Defense World
Alpha Tau Medical Shares Fall After Piper Sandler Downgrade - marketscreener.com
Piper Sandler cuts Alpha Tau Medical stock rating on valuation - Investing.com South Africa
DRTS Receives Downgrade from Piper Sandler with Neutral Rating | - GuruFocus
Alpha Tau Medical Ltd Stock (DRTS) Financials Data
Revenue
Net Income
Cash Flow
EPS
1.82%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):